Schedule 4 to the Principal Order is amended as follows:

(a) by omitting item 40007 and substituting the following:

40007.

Acetanilide and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

(b) by inserting after item 40121 the following:

40121E.

Articaine.

(c) by inserting after item 40190 the following:

40190V.

Bevacizumab.

(d) by omitting item 40194 and substituting the following:

40194.	Bifonazole except –
	(a) when included in Schedule 2 ; or
	(b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or
	(c) in preparations for dermal use for the treatment of tinea pedis.

(e) by inserting after item 40229 the following:

40229M.	Butoconazole.
40229S.	Butraconazole.

(f) by inserting after item 40266 the following:

40266E.

Carbuterol.

(g) by inserting after item 40308 the following:

40308E.

Cetuximab.

(h) by inserting after item 40346 the following:

40346S.

Cinacalcet.

(i) by omitting item 40358 and substituting the following:

40358.

Clemastine.

(j) by omitting item 40384 and substituting the following:

40384.	Clotrimazole –
	(a) except when included in Schedule 2 , 3 or 6 ; or
	(b) in preparations for dermal use for the treatment of tinea pedis.

(k) by inserting after item 40432H the following:

40432M.

Darifenacin.

(l) by inserting after item 40469 the following:

40469M.

Dichlorophen for internal human therapeutic use.

(m) by inserting after item 40501 the following:

40501M.

Dimethothiazine.

(n) by omitting item 40517 and substituting the following:

40517.

Diphenylpyraline.

(o) by omitting item 40552 and substituting the following:

40552.	Econazole –
	(a) except when included in Schedule 2 , 3 or 6 ; or
	(b) in preparations for dermal use for the treatment of tinea pedis.

(p) by omitting item 40608 and substituting the following:

40608.

Ethyl chloride for human therapeutic use.

(q) by inserting after item 40621 the following:

40621M.

Everolimus.

(r) by omitting item 40658 and substituting the following:

40658.

Flunisolide.

(s) by inserting after item 40744 the following:

40744E.

Halofuginone in preparations containing 0.1% or less of halofuginone for the treatment of animals.

(t) by inserting after item 40756 the following:

40756E.

Hexoprenaline.

(u) by omitting item 40762 and substituting the following:

40762.

Hydrargaphen.

(v) by inserting after item 40788H the following:

40788S.

Imidapril.

(w) by omitting item 40835 and substituting the following:

40835.	Ketoconazole except –
	(a) when included in Schedule 2 ; or
	(b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or
	(c) in preparations for dermal use for the treatment of tinea pedis.

(x) by inserting after item 40846 the following:

40846M.

Laronidase.

(y) by inserting after item 40933 the following:

40933M.

Mequitazine.

(z) by omitting item 40997 and substituting the following:

40997.	Miconazole –
	(a) except when included in Schedule 2 , 3 or 6 ; or
	(b) in preparations for dermal use for the treatment of tinea pedis.

(za) by omitting item 41063 and substituting the following:

41063.	Nicotine for use as an aid in withdrawal from tobacco smoking (including preparations for nasal administration), except –
	(a) when included in Schedule 2 ; or
	(b) in chewing gum; or
	(c) in lozenges; or
	(d) for sublingual use; or
	(e) in preparations for transdermal use.

(zb) by inserting after item 41089 the following:

41089S.

Norelgestromin.

(zc) by omitting item 41135 and substituting the following:

41135.

Oxiconazole except in preparations for dermal use for the treatment of tinea pedis.

(zd) by inserting after item 41170 the following:

41170E.

Pentaerythritol tetranitrate.

(ze) by omitting items 41206 and 41207 and substituting the following:

41206.	Phenylpropanolamine.
41207.	Phenyltoloxamine.

(zf) by inserting after item 41246 the following:

41246M.

Poractant alfa.

(zg) by inserting after item 41260 the following:

41260S.

Pregabalin.

(zh) by omitting item 41305 and substituting the following:

41305.

Pseudoephedrine except when included in Schedule 3 .

(zi) by omitting item 41490 and substituting the following:

41490.

Thenyldiamine.

(zj) by omitting item 41530 and substituting the following:

41530.	Tioconazole –
	(a) except when included in Schedule 2 or 3 ; or
	(b) in preparations for dermal use for the treatment of tinea pedis.